シノケムとＤＳＭは近く香港に折半出資会社を設立し、ＤＳＭの世界の抗感染症薬事業を引き継ぐ。同事業の社員2000人も合弁会社に移籍する。合弁化の手続きは2011年前半までに完了する見通し。
シノケムは農薬などを手掛け、2009年の売上高は2430億元（約３兆円）。今回の提携で医薬品事業を強化する。ＤＳＭの年間売上高は約80億ユーロで、抗感染症薬事業は中国企業などとの競争で採算が悪化していたという。
ＤＳＭは６年間にわたってパートナーを探していた。同社は中国シノケムと合弁を設立する。
ＤＳＭの発表によると、同社は10−12月（第４四半期）に5500万ユーロの一時利益を計上する。
ＤＳＭは世界で最も成長ペースが速い中国市場での売上高増加を狙っており、医薬品部門の2015年の利益率目標達成に貢献するとみられる。ペニシリン事業 は医薬品部門の一部で、同部門の７−９月期業績は営業損益が600万ユーロの赤字、売上高は１億6800万ユーロだった。同部門の売上高は同社全体の 7.7％。
2010/12/17
DSM to form global anti-infectives joint venture with Sinochem Group
Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in the Netherlands, today announces that it has reached an agreement with Sinochem Group to form a 50/50 global joint venture for its business group DSM Anti-Infectives. The transaction is subject to receipt of regulatory approvals (including approvals from regulatory authorities in China) and customary clearances from competition authorities in the EU and elsewhere. In addition, DSM's works councils will be requested to render advice in relation to the proposed transaction.The parties anticipate closing to take place in Q2 2011. Upon closing, the transaction will have retro-active effect to 1 January 2011.
As part of the joint venture agreement, Sinochem Group will take a 50% equity interest in DSM Anti-Infectives for a total cash consideration of ? 210 million on a cash and debt-free basis.
The joint venture will be headquartered in Hong Kong. Current DSM Anti-Infectives employees, in total around 2,000 people globally, will be part of the new entity. The joint venture will include all of the current DSM Anti-Infectives activities across the world.
The JV with Sinochem is fully in line with DSM’s stated strategy for its Pharma cluster: creating value via partnerships. The combination of DSM's strong global market position in anti-infectives and Sinochem's significant - sales - infrastructure presents exciting future growth opportunities through combined technologies and access to the fast growing Asian economies. DSM Anti-Infectives, the global leader in beta-lactam antibiotics, has successfully applied its highly innovative biotechnology knowledge to improve and transform its business.
Stephan Tanda, Member of the DSM Managing Board and responsible for the Pharma cluster, commented: “The intended joint venture with Sinochem Group is an important step for DSM and our anti-infectives business. This partnership will benefit from the strengths of both Sinochem and DSM and will allow us to grasp market opportunities in China and other high growth economies, in addition to securing European and American access to high quality products. Together with Sinochem Group we will accelerate the realization of this global joint venture’sgrowth strategy. I have every confidence in a successful partnership.”
Mr. Pan Zhengyi, Vice President of Sinochem Group, said: “The Chinese central government has the great initiative to promote seven key industries of strategic importance. Biotechnology is directly involved in four of these industries and related with the other three. The forming of this global joint venture is momentous for Sinochem with respect to its effort to build up its presence in biotech industry. It is also a strong testimony that Sinochem is ready to perform its social responsibility to save the energy consumption and reduce waste discharge by leveraging biotechnology. We have full confidence in DSM’s capability in terms of fermentation and biocatalytic conversion. The partnership will further promote the technical breakthrough in the anti-infectives sector and it is a strong force pushing Sinochem’s strategic development in the biochemical industry.”
Both companies are convinced that together they will be better able to capture the growth opportunities in China and other high growth economies, combining DSM’s proprietary technology position and global production footprint and Sinochem’s distribution and sales capabilities and global growth ambition in bio-pharmaceuticals. Further announcements on organization and management will be made at closing.
Additional information
Today DSM will hold a conference call for the media from 09.00 AM
?
09.30 AM CET and a conference call for investors and analysts
from 10.00 ?
10.45 AM. Details on how to access these calls can be found on
the DSM website, www.dsm.com.
Also, more information can be found in the presentation that can be
downloaded (PDF: 351 Kb) from the Investors
section of the DSM website.
Sinochem Group
Incorporated in 1950, Sinochem Group is one of China’s biggest
central state-owned enterprises. Sinochem has five business
segments including agricultural, energy, chemical (including
pharmaceutical distribution), real estate and finance Sinochem
has more than 200 subsidiaries and branches both in China and
abroad, among which there are four listed companies, namely
Sinochem International (SSE, 600500), SinoFert (HKEX, 00297),
Franshion Properties (HKEX, 00817) and GMG. On June 1st, 2009,
Sinochem made a major move to inject most of its assets into a
shareholding entity, “Sinochem Corporation”. More than 40,000
employees emulate Sinochem’s spirit of exploration and
innovation, adopt the mindset of “Creating Value, Pursuing
Excellence” and try their utmost to enhance the corporate value
and to build an iconic company worldwide. More information: www.sinochem.com.
---
Sinochem Group, on December 17th, has reached an
agreement with Royal DSM N.V., the global Life Sciences and
Materials Sciences Company. to form a 50/50 global
anti-infectives joint venture. The transaction is subject to
receipt of regulatory approvals (including approvals from regulatory
authorities in China and customary clearances from competition
authorities in the EU and elsewhere). In addition, DSM's works
councils will be requested to render advice in relation to the
proposed transaction. The parties anticipate closing to take
place in Q2 2011. Upon closing, the transaction will have
retro-active effect to 1 January 2011.
As part of the joint venture agreement, Sinochem Group will take
a 50% equity interest in DSM Anti-Infectives for a total cash
consideration of ? 210 million on a cash and debt-free basis.
The joint venture will be headquartered in Hong Kong. Current DSM Anti-Infectives employees, in total around 2,000 people globally, will be part of the new entity. The joint venture will include all of the current DSM Anti-Infectives activities across the world.
The JV with DSM is fully in line with Sinochem Group’s long-term development strategy in the biochemical industry. The combination of Sinochem Group's significant sales infrastructure and access to the fast growing Asian economies, and DSM's strong technology capacity and global market position in anti-infectives presents exciting future growth opportunities.
Mr. Pan Zhengyi, Vice President of Sinochem Group, said: “The Chinese central government has the great initiative to promote seven key industries of strategic importance. Biotechnology is directly involved in four of these industries. The forming of this global joint venture is momentous for Sinochem Group with respect to its effort to build up its presence in biochemical industry. It is also a strong testimony that Sinochem Group is ready to perform its social responsibility to save energy consumption and reduce waste discharge by leveraging biotechnology. We have full confidence in DSM’s capability in terms of fermentation and bio-catalytic conversion. The partnership will further promote the technical breakthrough in the anti-infectives sector and it is a strong force pushing Sinochem Group’s strategic development in the biochemical industry.”
Stephan Tanda, Member of the DSM Managing Board and responsible for the Pharma cluster, commented: “The intended joint venture with Sinochem Group is an important step for DSM and our anti-infectives business. This partnership will benefit from the strengths of both Sinochem Group and DSM and will allow us to grasp market opportunities in China and other high growth economies, in addition to securing European and American access to high quality products. Together with Sinochem Group we will accelerate the realization of this global joint venture’s growth strategy. I have every confidence in a successful partnership.”
Both companies are convinced that together they will be better able to capture the growth opportunities in China and other high growth economies, combining Sinochem Group’s distribution and sales capabilities and global growth ambition in biochemical industry and DSM’s proprietary technology position and global production footprint. Further announcements on organization and management will be made at closing.